Prognostic value of cancer stem cell marker CD133 expression in esophageal carcinoma: A meta-analysis

Sui, Yun‐Peng; Xue-ping, Jian; I, L; Guizhen, Xu; Liao, Huaiwei; Liu, Yan-Ping; Wen, Huicai

doi:10.3892/mco.2015.651

Cited by 16 publications

(14 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two meta-analyses have shown that higher CD133 levels are significantly associated with lymph node metastasis, clinical stage, and histopathological grade in colorectal cancer and esophageal carcinoma patients [17, 18]. …”

Section: Introductionmentioning

confidence: 99%

The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients

et al. 2017

View full text Add to dashboard Cite

BackgroundCD133 (prominin-1) is widely believed to be a cancer stem cell marker in various solid tumor types, and CD133 has been correlated with tumor-initiating capacity. Recently, the nuclear location of CD133 expression in tumors has been discussed, but hepatocellular carcinoma (HCC) has not been included in these discussions. The goal of this study was to investigate the location of CD133 expression in HCC and this location’s potential value as a prognostic indicator of survival in patients with HCC.MethodsWe enrolled 119 cancerous tissues and pair-matched adjacent normal liver tissue from HCC patients. These tissues were obtained immediately after operation, and tissue microarrays were subsequently constructed. The expression of CD133 was measured by immunohistochemistry (IHC), and the correlations between this expression and clinical characteristics and prognosis was estimated using statistical analysis.ResultsThe results showed that the CD133 protein expression levels of HCC in both the cytoplasm and nucleus were significantly higher than adjacent normal liver tissue. Kaplan–Meier survival and Cox regression analyses revealed that high CD133 expression in the cytoplasm was an independent predictor of poor prognosis for the overall survival (OS) and relapse-free survival (RFS) rates of HCC patients (P = 0.028 and P = 0.046, respectively). Surprisingly, high nuclear CD133 expression of HCC was an independent predictor of the good prognosis of the OS and RFS rates of HCC patients (P = 0.023 and P = 0.012, respectively).ConclusionsThe clinical evidence that revealed cytoplasmic CD133 expression was correlated with poor prognosis, while nuclear CD133 expression was significantly correlated with favorable prognosis.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-017-3460-9) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients

et al. 2017

View full text Add to dashboard Cite

show abstract

“…For example, PROM1 upregulation has been reported in ovarian cancer [88,89] and targeting this gene retards ovarian cancer development in an in vivo model [90]. Furthermore, PROM1 has been identified as a stem cell marker in esophageal and breast cancers [5,56]. Next, we observed that PROM2 upregulation was associated with poor OS in lung cancer; however, owing to contradictory results, its role in breast cancer was not clear and the receptor status of breast cancer cells also had some Fig.…”

Section: Discussionmentioning

confidence: 76%

“…These results regarding PROM1 and PROM2 expression are also supported by previous studies. For example, PROM1 overexpression has been shown in esophageal and ovarian cancers [56,57]. Moreover, PROM1+ ovarian CSCs are highly tumorigenic, chemoresistant, and metastatic and they promote the adhesion capabilities of the ovarian cancer metastatic niche [57].…”

Section: Prominin Mrna Expression Analysismentioning

confidence: 99%

PROM1 and PROM2 expression differentially modulates clinical prognosis of cancer: a multiomics analysis

et al. 2019

View full text Add to dashboard Cite

Prominin 1 (PROM1) is considered a biomarker for cancer stem cells, although its biological role is unclear. Prominin 2 (PROM2) has also been associated with certain cancers. However, the prognostic value of PROM1 and PROM2 in cancer is controversial. Here, we performed a systematic data analysis to examine whether prominins can function as prognostic markers in human cancers. The expression of prominins was assessed and their prognostic value in human cancers was determined using univariate and multivariate survival analyses, via various online platforms. We selected a group of prominent functional protein partners of prominins by protein-protein interaction analysis. Subsequently, we investigated the relationship between mutations and copy number alterations in prominin genes and various types of cancers. Furthermore, we identified genes that correlated with PROM1 and PROM2 in certain cancers, based on their levels of expression. Gene ontology and pathway analyses were performed to assess the effect of these correlated genes on various cancers. We observed that PROM1 was frequently overexpressed in esophageal, liver, and ovarian cancers and its expression was negatively associated with prognosis, whereas PROM2 overexpression was associated with poor overall survival in lung and ovarian cancers. Based on the varying characteristics of prominins, we conclude that PROM1 and PROM2 expression differentially modulates the clinical outcomes of cancers.

show abstract

“…In particular, some studies have proposed CD44 as a CSC marker in ESCC [ 29 , 31 ]. Functional characteristics were also found for CD133 [ 32 , 33 , 34 ], CD271(p75NTR) [ 35 , 36 , 37 ], LgR5 [ 38 , 39 , 40 ], CD90 [ 41 , 42 ], ALDH1 [ 43 , 44 , 45 ], ABCG2 [ 33 , 46 , 47 ], ICAM-1[ 48 ] and ITGA7 [ 49 ]. Besides, CD44 and CD133 can be used in combination with CD24 (CD44 + /CD24 − ) [ 50 ], CD133 (CD44 + /CD133 + )[ 51 ] and CXCR4 (CD133 + /CXCR4 + ) [ 52 ] to identify esophageal CSCs ( Table 1 ).…”

Section: Isolation Of Esophageal Cancer Stem Cellsmentioning

confidence: 99%

Linking Cancer Stem Cell Plasticity to Therapeutic Resistance-Mechanism and Novel Therapeutic Strategies in Esophageal Cancer

Zhou

Fan

Liu

et al. 2020

Cells

View full text Add to dashboard Cite

Esophageal cancer (EC) is an aggressive form of cancer, including squamous cell carcinoma (ESCC) and adenocarcinoma (EAC) as two predominant histological subtypes. Accumulating evidence supports the existence of cancer stem cells (CSCs) able to initiate and maintain EAC or ESCC. In this review, we aim to collect the current evidence on CSCs in esophageal cancer, including the biomarkers/characterization strategies of CSCs, heterogeneity of CSCs, and the key signaling pathways (Wnt/β-catenin, Notch, Hedgehog, YAP, JAK/STAT3) in modulating CSCs during esophageal cancer progression. Exploring the molecular mechanisms of therapy resistance in EC highlights DNA damage response (DDR), metabolic reprogramming, epithelial mesenchymal transition (EMT), and the role of the crosstalk of CSCs and their niche in the tumor progression. According to these molecular findings, potential therapeutic implications of targeting esophageal CSCs may provide novel strategies for the clinical management of esophageal cancer.

show abstract

Prognostic value of cancer stem cell marker CD133 expression in esophageal carcinoma: A meta-analysis

Cited by 16 publications

References 23 publications

The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients

The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients

PROM1 and PROM2 expression differentially modulates clinical prognosis of cancer: a multiomics analysis

Linking Cancer Stem Cell Plasticity to Therapeutic Resistance-Mechanism and Novel Therapeutic Strategies in Esophageal Cancer

Contact Info

Product

Resources

About